BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Soest EM, van Rossum LG, Dieleman JP, van Oijen MG, Siersema PD, Sturkenboom MC, Kuipers EJ. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol. 2008;103:966-973. [PMID: 18070237 DOI: 10.1111/j.1572-0241.2007.01665.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, Pontone S, Severi C. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J Gastroenterol 2019; 25(22): 2706-2719 [PMID: 31235994 DOI: 10.3748/wjg.v25.i22.2706] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 42] [Article Influence: 18.3] [Reference Citation Analysis]
2 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
3 Islam MM, Poly TN, Walther BA, Dubey NK, Anggraini Ningrum DN, Shabbir SA, Jack Li YC. Adverse outcomes of long-term use of proton pump inhibitors: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:1395-1405. [PMID: 30028775 DOI: 10.1097/meg.0000000000001198] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
4 Hwang IC, Chang J, Park SM. Emerging hazard effects of proton pump inhibitor on the risk of colorectal cancer in low-risk populations: A Korean nationwide prospective cohort study. PLoS One 2017;12:e0189114. [PMID: 29216279 DOI: 10.1371/journal.pone.0189114] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
5 Lai SW, Liao KF, Lai HC, Lin CL, Sung FC. Use of proton pump inhibitors correlates with increased risk of colorectal cancer in Taiwan. Asia Pac J Clin Oncol 2013;9:192-3. [PMID: 23298363 DOI: 10.1111/ajco.12054] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
6 Babic A, Zhang X, Morales-Oyarvide V, Yuan C, Khalaf N, Khalili H, Lochhead P, Chan AT, Ogino S, Wolpin BM, Wu K, Fuchs CS, Giovannucci EL, Stampfer MJ, Ng K. Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies. Br J Cancer 2020;123:844-51. [PMID: 32541871 DOI: 10.1038/s41416-020-0939-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Ma T, Wu M, Jia S, Yang L. Proton pump inhibitors and the risk of colorectal cancer: a systematic review and meta-analysis of observational studies. Int J Colorectal Dis 2020;35:2157-69. [DOI: 10.1007/s00384-020-03717-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
8 Schneider JL, Kolitsopoulos F, Corley DA. Risk of gastric cancer, gastrointestinal cancers and other cancers: A comparison of treatment with pantoprazole and other proton pump inhibitors. Aliment Pharmacol Ther. 2016;43:73-82. [PMID: 26541643 DOI: 10.1111/apt.13450] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
9 Hart AM. Evidence-based recommendations for GERD treatment. Nurse Pract. 2013;38:26-34; quiz 34. [PMID: 23812348 DOI: 10.1097/01.npr.0000431881.25363.84] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
10 Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139:1115-1127. [PMID: 20727892 DOI: 10.1053/j.gastro.2010.08.023] [Cited by in Crossref: 137] [Cited by in F6Publishing: 119] [Article Influence: 11.4] [Reference Citation Analysis]
11 Ahn JS, Park SM, Eom CS, Kim S, Myung SK. Use of Proton Pump Inhibitor and Risk of Colorectal Cancer: A Meta-analysis of Observational Studies. Korean J Fam Med 2012;33:272-9. [PMID: 23115701 DOI: 10.4082/kjfm.2012.33.5.272] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
12 Kearns MD, Boursi B, Yang YX. Proton pump inhibitors on pancreatic cancer risk and survival. Cancer Epidemiol 2017;46:80-4. [PMID: 28056391 DOI: 10.1016/j.canep.2016.12.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
13 de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of colorectal cancer in patients with Barrett's esophagus: A Dutch population-based study. Am J Gastroenterol 2010;105:77-83. [PMID: 19724268 DOI: 10.1038/ajg.2009.503] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
14 Reimer C. Safety of long-term PPI therapy. Best Practice & Research Clinical Gastroenterology 2013;27:443-54. [DOI: 10.1016/j.bpg.2013.06.001] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 6.6] [Reference Citation Analysis]
15 Paterson AC, Macrae FA, Pizzey C, Baldwin GS, Shulkes A. Circulating gastrin concentrations in patients at increased risk of developing colorectal carcinoma: Gastrins and colorectal carcinoma risk. J Gastroenterol Hepatol 2014;29:480-6. [DOI: 10.1111/jgh.12417] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
16 Haastrup PF, Jarbøl DE, Thompson W, Hansen JM, Søndergaard J, Rasmussen S. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol 2021;8:e000563. [PMID: 33589415 DOI: 10.1136/bmjgast-2020-000563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Shiratori Y, Ikeya T, Ishii N, Yamamoto K, Honda T, Hasatani K, Yoshida N, Nishida T, Sumiyoshi T, Kiyotoki S, Arai M, Niikura R. Association between the chronic use of gastric acid suppressants and high-risk colorectal polyps. JGH Open 2021;5:371-6. [PMID: 33732884 DOI: 10.1002/jgh3.12503] [Reference Citation Analysis]
18 Yee YK, Tan VP, Chan P, Hung IF, Pang R, Wong BC. Epidemiology of colorectal cancer in Asia. J Gastroenterol Hepatol. 2009;24:1810-1816. [PMID: 20002940 DOI: 10.1111/j.1440-1746.2009.06138.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
19 Hálfdánarson ÓÖ, Fall K, Ogmundsdottir MH, Lund SH, Steingrímsson E, Ogmundsdottir HM, Zoega H. Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: An Icelandic population‐based case‐control study. Pharmacoepidemiol Drug Saf 2019;28:471-8. [DOI: 10.1002/pds.4702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
20 Kao WY, Su CW, Chia-Hui Tan E, Lee PC, Chen PH, Tang JH, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. Hepatology 2019;69:1151-64. [PMID: 30175498 DOI: 10.1002/hep.30247] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
21 Poulsen AH, Christensen S, McLaughlin JK, Thomsen RW, Sørensen HT, Olsen JH, Friis S. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer. 2009;100:1503-1507. [PMID: 19352380 DOI: 10.1038/sj.bjc.6605024] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 6.3] [Reference Citation Analysis]
22 Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122:896-903. [PMID: 19786155 DOI: 10.1016/j.amjmed.2009.04.014] [Cited by in Crossref: 114] [Cited by in F6Publishing: 93] [Article Influence: 8.8] [Reference Citation Analysis]
23 Roulet L, Vernaz N, Giostra E, Gasche Y, Desmeules J. [Adverse effects of proton pump inhibitors: should we worry about long-term exposure?]. Rev Med Interne 2012;33:439-45. [PMID: 22284952 DOI: 10.1016/j.revmed.2011.12.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
24 Tepeš B. Long-Term Acid Inhibition: Benefits and Harms. Dig Dis 2011;29:476-81. [DOI: 10.1159/000331519] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
25 Laiyemo AO, Kamangar F, Marcus PM, Taylor PR, Virtamo J, Albanes D, Stolzenberg-Solomon RZ. Atrophic gastritis and the risk of incident colorectal cancer. Cancer Causes Control 2010;21:163-70. [PMID: 19838812 DOI: 10.1007/s10552-009-9446-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
26 Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, Bazzoli F. Proton pump inhibitors: Risks of long-term use: Proton pump inhibitors. Journal of Gastroenterology and Hepatology 2017;32:1295-302. [DOI: 10.1111/jgh.13737] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 15.4] [Reference Citation Analysis]
27 Chubak J, Boudreau DM, Rulyak SJ, Mandelson MT. Colorectal cancer risk in relation to use of acid suppressive medications. Pharmacoepidemiol Drug Saf 2009;18:540-4. [PMID: 19367565 DOI: 10.1002/pds.1749] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
28 Mulder SA, van Soest EM, Dieleman JP, van Rossum LG, Ouwendijk RJ, van Leerdam ME, Kuipers EJ. Exposure to colorectal examinations before a colorectal cancer diagnosis: a case–control study. European Journal of Gastroenterology & Hepatology 2010;22:437-43. [DOI: 10.1097/meg.0b013e328333fc6a] [Cited by in Crossref: 39] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
29 Song HJ, Jeon N, Squires P. The association between acid-suppressive agent use and the risk of cancer: a systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:1437-56. [PMID: 32548678 DOI: 10.1007/s00228-020-02927-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Meriggi F. Controversial link between proton pump inhibitors and anticancer agents: review of the literature. Tumori 2021;:3008916211025091. [PMID: 34159850 DOI: 10.1177/03008916211025091] [Reference Citation Analysis]
31 Lei WY, Wang JH, Yi CH, Liu TT, Hung JS, Wong MW, Bair MJ, Vaezi MF, Orr WC, Chen CL. Association between use of proton pump inhibitors and colorectal cancer: A nationwide population-based study. Clin Res Hepatol Gastroenterol 2021;45:101397. [PMID: 32224118 DOI: 10.1016/j.clinre.2020.02.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
32 Ellrichmann M, Ritter PR, Schrader H, Schmidt WE, Meier JJ, Schmitz F. Gastrin stimulates the VEGF-A promotor in a human colon cancer cell line. Regul Pept. 2010;165:146-150. [PMID: 20600355 DOI: 10.1016/j.regpep.2010.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
33 Heidelbaugh JJ, Metz DC, Yang YX. Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? Int J Clin Pract. 2012;66:582-591. [PMID: 22607510 DOI: 10.1111/j.1742-1241.2012.02921.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
34 Wang X, Liu Q, Halfdanarson ÓÖ, Zoega H, Sadr-Azodi O, Engstrand L, Fall K, Brusselaers N. Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study. Br J Cancer 2021. [PMID: 34253872 DOI: 10.1038/s41416-021-01480-0] [Reference Citation Analysis]
35 Zeng R, Cheng Y, Luo D, Wang J, Yang J, Jiang L, Zhuo Z, Guo K, Wu H, Leung FW, Sha W, Chen H. Comprehensive analysis of proton pump inhibitors and risk of digestive tract cancers. Eur J Cancer 2021;156:190-201. [PMID: 34481369 DOI: 10.1016/j.ejca.2021.07.030] [Reference Citation Analysis]
36 Bradley MC, Murray LJ, Cantwell MM, Hughes CM. Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case-control study. Br J Cancer 2012;106:233-9. [PMID: 22108522 DOI: 10.1038/bjc.2011.511] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
37 Chueca E, Lanas A, Piazuelo E. Role of gastrin-peptides in Barrett's and colorectal carcinogenesis. World J Gastroenterol 2012; 18(45): 6560-6570 [PMID: 23236230 DOI: 10.3748/wjg.v18.i45.6560] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
38 Triadafilopoulos G, Roorda AK, Akiyama J. Indications and safety of proton pump inhibitor drug use in patients with cancer. Expert Opin Drug Saf. 2013;12:659-672. [PMID: 23647006 DOI: 10.1517/14740338.2013.797961] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
39 Raoul JL, Edeline J, Gilabert M, Senellart H, Frenel JS. [Proton pump inhibitors and cancers: A hazardous association?]. Bull Cancer 2020;107:458-64. [PMID: 32057465 DOI: 10.1016/j.bulcan.2019.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs 2012;72:437-45. [PMID: 22356286 DOI: 10.2165/11599320-000000000-00000] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
41 von Rahden BH, Scheurlen M, Filser J, Stein HJ, Germer CT. [Newly recognized side-effects of proton pump inhibitors. Arguments in favour of fundoplication for GERD?]. Chirurg. 2012;83:38-44. [PMID: 21909830 DOI: 10.1007/s00104-011-2173-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
42 Joo MK, Park JJ, Chun HJ. Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors. Dig Dis 2018;36:1-14. [PMID: 28881340 DOI: 10.1159/000480149] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
43 Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe N, Fujiwara Y, Nagahara A, Kawamura O, Iwakiri R, Ozawa S, Ashida K, Ohara S, Kashiwagi H, Adachi K, Higuchi K, Miwa H, Fujimoto K, Kusano M, Hoshihara Y, Kawano T, Haruma K, Hongo M, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751-767. [PMID: 27325300 DOI: 10.1007/s00535-016-1227-8] [Cited by in Crossref: 142] [Cited by in F6Publishing: 115] [Article Influence: 23.7] [Reference Citation Analysis]
44 Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56:931-950. [PMID: 21365243 DOI: 10.1007/s10620-010-1560-3] [Cited by in Crossref: 187] [Cited by in F6Publishing: 167] [Article Influence: 17.0] [Reference Citation Analysis]
45 Graham C, Orr C, Bricks CS, Hopman WM, Hammad N, Ramjeesingh R. A retrospective analysis of the role of proton pump inhibitors in colorectal cancer disease survival. Curr Oncol 2016;23:e583-8. [PMID: 28050148 DOI: 10.3747/co.23.3204] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
46 Kuiper JG, Herk‐sukel MPP, Lemmens VEPP, Kuipers EJ, Herings RMC. Proton pump inhibitors are not associated with an increased risk of colorectal cancer. GastroHep 2020;2:165-70. [DOI: 10.1002/ygh2.409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
47 Abrahami D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, Azoulay L. Proton pump inhibitors and risk of colorectal cancer. Gut 2021:gutjnl-2021-325096. [PMID: 34210775 DOI: 10.1136/gutjnl-2021-325096] [Reference Citation Analysis]